Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future

References

• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364(9451):2106–12. doi:10.1016/S0140-6736(04)17551-X. PubMed PMID: 15589308.
   PubMed Web of Science ®Google Scholar
• Matiello M, Jacob A, Wingerchuk DM, et al. Neuromyelitis optica. Curr Opin Neurol 2007;20(3):255–60. doi:10.1097/WCO.0b013e32814f1c6b. PubMed PMID: 17495617.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Makris N. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008;118(4):209–17. doi:10.1111/j.1600-0404.2008.01002.x. PubMed PMID: 18336627.
   PubMed Web of Science ®Google Scholar
• Kim SH, Huh SY, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 2013;70(9):1110–17. doi:10.1001/jamaneurol.2013.3071. PubMed PMID: 23897062.
   PubMed Web of Science ®Google Scholar
• Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64(7):1270–2. doi:10.1212/01.WNL.0000159399.81861.D5. PubMed PMID: 15824362.
   PubMed Web of Science ®Google Scholar
• Ringelstein M, Harmel J, Distelmaier F, et al. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scler 2013;19(11):1544–7. doi:10.1177/1352458513498125. PubMed PMID: 23886825.
   PubMed Web of Science ®Google Scholar
• Mahmood NA, Silver K, Onel K, et al. Efficacy and safety of rituximab in pediatric neuromyelitis optica. J Child Neurol 2011;26(2):244–7. doi:10.1177/0883073810381445. PubMed PMID: 21183724.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013;12(6):554–62. doi:10.1016/S1474-4422(13)70076-0. PubMed PMID: 23623397.
   PubMed Web of Science ®Google Scholar
• Wang HH, Dai YQ, Qiu W, et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci 2011;18(10):1313–7. doi:10.1016/j.jocn.2011.01.031. PubMed PMID: 21795048.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang H, Long Y, et al. Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2011;234(1–2):155–60. doi:10.1016/j.jneuroim.2011.03.009. PubMed PMID: 21489641.
   PubMed Web of Science ®Google Scholar
• Linhares UC, Schiavoni PB, Barros PO, et al. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol 2013;33(1):179–89. doi:10.1007/s10875-012-9780-2. PubMed PMID: 22948743.
   PubMed Web of Science ®Google Scholar
• Wong CK, Lit LC, Tam LS, et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008;127(3):385–93. doi:10.1016/j.clim.2008.01.019. PubMed PMID: 18373953.
   PubMed Web of Science ®Google Scholar
• Kaplin AI, Deshpande DM, Scott E, et al. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 2005;115(10):2731–41. doi:10.1172/JCI25141. PubMed PMID: 16184194.
   PubMed Web of Science ®Google Scholar
• Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 2014;82(15):1302–6. doi:10.1212/WNL.0000000000000317. PubMed PMID: 24634453.
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Zhang H, Saadoun S, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012;71(3):314–22. doi:10.1002/ana.22657. PubMed PMID: 22271321.
   PubMed Web of Science ®Google Scholar
• Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189(11):1747–56. PubMed PMID: 10359578.
   PubMed Web of Science ®Google Scholar
• Okada K, Matsushita T, Kira J, et al. B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology 2010;74(2):177–8. doi:10.1212/WNL.0b013e3181c919ee. PubMed PMID: 20065253.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang K, Zhong X, et al. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol 2012;32(5):1007–11. doi:10.1007/s10875-012-9709-9. PubMed PMID: 22644841.
   PubMed Web of Science ®Google Scholar
• Quan C, ZhangBao J, Lu J, et al. The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy. J Neuroimmunol 2015;282:45–53. doi:10.1016/j.jneuroim.2015.03.016. PubMed PMID: 25903728.
   PubMed Web of Science ®Google Scholar
• Ishizu T, Osoegawa M, Mei FJ, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005;128(Pt 5):988–1002. doi:10.1093/brain/awh453. PubMed PMID: 15743872.
   PubMed Web of Science ®Google Scholar
• Herges K, de Jong BA, Kolkowitz I, et al. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler 2012;18(4):398–408. doi:10.1177/1352458512440060. PubMed PMID: 22343184.
   PubMed Web of Science ®Google Scholar
• Saadoun S, Waters P, MacDonald C, et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol 2012;71(3):323–33. doi:10.1002/ana.22686. PubMed PMID: 22374891.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6(9):805–15. doi:10.1016/S1474-4422(07)70216-8. PubMed PMID: 17706564.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Mori M, Ito M, et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 2009;256(12):2082–4. doi:10.1007/s00415-009-5274-4. PubMed PMID: 19655191.
   PubMed Web of Science ®Google Scholar
• Barros PO, Cassano T, Hygino J, et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol 2016;183(3):480–9. doi:10.1111/cei.12733. PubMed PMID: 26472479.
   PubMed Web of Science ®Google Scholar
• Ishizu T, Osoegawa M, Mei FJ, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005;128(Pt 5):988–1002. doi:10.1093/brain/awh453. PubMed PMID: 15743872.
   PubMed Web of Science ®Google Scholar
• Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011;108(9):3701–6. doi:10.1073/pnas.1017385108. PubMed PMID: 21321193.
   PubMed Web of Science ®Google Scholar
• Spolski R, Leonard WJ. IL-21 and T follicular helper cells. Int Immunol 2010;22(1):7–12. doi:10.1093/intimm/dxp112. PubMed PMID: 19933709.
   PubMed Web of Science ®Google Scholar
• Stromnes IM, Cerretti LM, Liggitt D, et al. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008;14(3):337–42. doi:10.1038/nm1715. PubMed PMID: 18278054.
   PubMed Web of Science ®Google Scholar
• Kroenke MA, Carlson TJ, Andjelkovic AV, et al. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 2008;205(7):1535–41. doi:10.1084/jem.20080159. PubMed PMID: 18573909.
   PubMed Web of Science ®Google Scholar
• Rothhammer V, Heink S, Petermann F, et al. Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med. 2011;208(12):2465–76. doi:10.1084/jem.20110434. PubMed PMID: 22025301.
   PubMed Web of Science ®Google Scholar
• Liu SM, King C. IL-21-producing Th cells in immunity and autoimmunity. J Immunol 2013;191(7):3501–6. doi:10.4049/jimmunol.1301454. PubMed PMID: 24058193.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 2010;16(12):1443–52. doi:10.1177/1352458510379247. PubMed PMID: 20739337.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130(Pt 5):1235–43. doi:10.1093/brain/awm062. PubMed PMID: 17449477.
   PubMed Web of Science ®Google Scholar
• Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab′)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002;51(1):15–24. doi:10.1007/s00262-001-0247-1. PubMed PMID: 11845256.
   PubMed Web of Science ®Google Scholar
• Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6(5):394–403. doi:10.1038/nri1838. PubMed PMID: 16622478.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387(10036):2402–11. doi:10.1016/S0140-6736(15)01317-3. PubMed PMID: 27080498.
   Google Scholar
• Shankar AG, Kirkwood AA, Depani S, et al. Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents – a report from the United Kingdom's Children's Cancer and Leukaemia Study Group. Br J Haematol 2016;173(3):421–31. doi:10.1111/bjh.13979. PubMed PMID: 26996288.
   PubMed Web of Science ®Google Scholar
• De Keyser F, Hoffman I, Durez P, et al. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry. J Rheumatol 2014;41(9):1761–5. doi:10.3899/jrheum.131279. PubMed PMID: 25128506.
   PubMed Web of Science ®Google Scholar
• Carubbi F, Alunno A, Cipriani P, et al. Rituximab in primary Sjögren's syndrome: a ten-year journey. Lupus 2014;23(13):1337–49. doi:10.1177/0961203314546023. PubMed PMID: 25096066.
   PubMed Web of Science ®Google Scholar
• He D, Yu Y, Yan W, et al. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report. Pediatr Neurol 2014;51(2):255–8. doi:10.1016/j.pediatrneurol.2014.01.039. PubMed PMID: 25079575.
   PubMed Web of Science ®Google Scholar
• Yang CS, Yang L, Li T, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 2013;81(8):710–3. doi:10.1212/WNL.0b013e3182a1aac7. PubMed PMID: 23884041.
   PubMed Web of Science ®Google Scholar
• Beres SJ, Graves J, Waubant E. Rituximab use in pediatric central demyelinating disease. Pediatr Neurol 2014;51(1):114–8. doi:10.1016/j.pediatrneurol.2014.02.007. PubMed PMID: 24768216.
   PubMed Web of Science ®Google Scholar
• Capobianco M, Malucchi S, di SA, et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci 2007;28(4):209–11. doi:10.1007/s10072-007-0823-z. PubMed PMID: 17690854.
   PubMed Web of Science ®Google Scholar
• Lindsey JW, Meulmester KM, Brod SA, et al. Variable results after rituximab in neuromyelitis optica. J Neurol Sci 2012;317(1–2):103–5. doi:10.1016/j.jns.2012.02.017. PubMed PMID: 22405926.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim HJ. Lack of response to rituximab therapy in patients with neuromyelitis optica: true non-responders or insufficient treatment. J Neurol Sci 2012;319(1–2):171; author reply 172. doi:10.1016/j.jns.2012.05.005. PubMed PMID: 22633442.
   PubMed Web of Science ®Google Scholar
• Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011;76(15):1310–5. doi:10.1212/WNL.0b013e3182152881. PubMed PMID: 21482945.
   PubMed Web of Science ®Google Scholar
• Etemadifar M, Nasr Z, Khalili B, et al. Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis. Mult Scler Int 2015;2015:174720. doi:10.1155/2015/174720. PubMed PMID: 25973275.
   PubMedGoogle Scholar
• Jacob A, McKeon A, Nakashima I, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2013;84(8):922–30. doi:10.1136/jnnp-2012-302310. PubMed PMID: 23142960.
   PubMed Web of Science ®Google Scholar
• Thongpooswan S, Chapagain B, Bandagi S. A rare case of neuromyelitis optica spectrum disorder in patient with Sjogren's syndrome. Case Rep Rheumatol 2014;2014:158165. doi:10.1155/2014/158165. PubMed PMID: 25506022.
   PubMedGoogle Scholar
• Kovacs KT, Kalluri SR, Boza-Serrano A, et al. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: a preliminary study. Mult Scler 2016; 22(9):1192–201. doi:10.1177/1352458515613165. PubMed PMID: 26514978.
   Google Scholar
• Saison J, Costedoat-Chalumeau N, Maucort-Boulch D, et al. Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. Lupus 2015;24(1):74–81. doi:10.1177/0961203314547795. PubMed PMID: 25117654.
   PubMed Web of Science ®Google Scholar
• Li H, Dai Y, Wu AM, et al. Anti-thyroid antibodies and cerebrospinal fluid findings in neuromyelitis optica spectrum disorders. J Neuroimmunol 2015;281:38–43. doi:10.1016/j.jneuroim.2015.02.014. PubMed PMID: 25867466.
   PubMed Web of Science ®Google Scholar
• Sudulagunta SR, Sodalagunta MB, Khorram H, et al. Autoimmune thyroiditis associated with neuromyelitis optica (NMO). Ger Med Sci 2015;13:Doc22. doi:10.3205/000226. PubMed PMID: 26633965.
   PubMedGoogle Scholar
• Nasir S, Kerr DA, Birnbaum J. Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus. Arch Neurol 2009;66(9):1160–3. doi:10.1001/archneurol.2009.194. PubMed PMID: 19752308.
   PubMedGoogle Scholar
• Birnbaum J, Kerr D. Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. Nat Clin Pract Rheumatol 2008;4(7):381–6. doi:10.1038/ncprheum0818. PubMed PMID: 18493269.
   PubMedGoogle Scholar
• Nosadini M, Alper G, Riney CJ, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2016;3(1):e188. doi:10.1212/NXI.0000000000000188. PubMed PMID: 26819962.
   PubMed Web of Science ®Google Scholar
• Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65(11):1443–8. doi:10.1001/archneur.65.11.noc80069. PubMed PMID: 18779415.
   PubMed Web of Science ®Google Scholar
• Fernández-Megía MJ, Casanova-Estruch B, Pérez-Miralles F, et al. Clinical evaluation of rituximab treatment for neuromyelitis optica. Neurologia 2015;30(8):461–4. doi:10.1016/j.nrl.2014.09.001. PubMed PMID: 25444411.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011;68(11):1412–20. doi:10.1001/archneurol.2011.154. PubMed PMID: 21747007.
   PubMedGoogle Scholar
• Rommer PS, Dörner T, Freivogel K, et al. Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a National Online Registry (GRAID). J Neuroimmune Pharmacol 2016;11(1):1–8. doi:10.1007/s11481-015-9646-5. PubMed PMID: 26589235.
   PubMed Web of Science ®Google Scholar
• Felli V, Di SA, Anselmi M, et al. Progressive multifocal leukoencephalopathy following treatment with Rituximab in an HIV-negative patient with non-Hodgkin lymphoma. A case report and literature review. Neuroradiol J 2014;27(6):657–64. PubMed PMID: 25489887.
   PubMedGoogle Scholar
• Henegar CE, Eudy AM, Kharat V, et al. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus 2016;25(6):617–26. doi:10.1177/0961203315622819. PubMed PMID: 26743322.
   PubMed Web of Science ®Google Scholar
• Kim SH, Hyun JW, Jeong IH, et al. Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder. J Neurol 2015;262(3):696–700. doi:10.1007/s00415-014-7629-8. PubMed PMID: 25559683.
   PubMed Web of Science ®Google Scholar
• Kim SH, Jeong IH, Hyun JW, et al. Treatment outcomes with Rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to Rituximab. JAMA Neurol 2015;72(9):989–95. doi:10.1001/jamaneurol.2015.1276. PubMed PMID: 26167726.
   PubMed Web of Science ®Google Scholar
• Cornec D, Tempescul A, Querellou S, et al. Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. Ann Hematol 2012;91(5):715–21. doi:10.1007/s00277-011-1369-y. PubMed PMID: 22083514.
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Ida H, Hirota Y, et al. Intracellular dynamics and fate of a humanized anti-interleukin-6 receptor monoclonal antibody, Tocilizumab. Mol Pharmacol 2015;88(4):660–75. doi:10.1124/mol.115.099184. PubMed PMID: 26180046.
   PubMed Web of Science ®Google Scholar
• Saraux A, Rouanet S, Flipo RM, et al. Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study. Clin Exp Rheumatol 2016;34(2):303–10. PubMed PMID: 26941130.
   PubMed Web of Science ®Google Scholar
• Hirabayashi Y, Munakata Y, Miyata M, et al. Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: a multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group. Mod Rheumatol 2016:1–8. doi:10.3109/14397595.2016.1160991. PubMed PMID: 26934116.
   PubMed Web of Science ®Google Scholar
• Araki M, Aranami T, Matsuoka T, et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2013;23(4):827–31. doi:10.1007/s10165-012-0715-9. PubMed PMID: 22782533.
   PubMed Web of Science ®Google Scholar
• Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol 2015;72(7):756–63. doi:10.1001/jamaneurol.2015.0533. PubMed PMID: 25985228.
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Stüve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 2013;70(3):390–3. doi:10.1001/jamaneurol.2013.668. PubMed PMID: 23599943.
   PubMed Web of Science ®Google Scholar
• Ayzenberg I, Kleiter I, Schröder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013;70(3):394–7. doi:10.1001/jamaneurol.2013.1246. PubMed PMID: 23358868.
   PubMed Web of Science ®Google Scholar
• Harmel J, Ringelstein M, Ingwersen J, et al. Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurol 2014;14:247. doi:10.1186/s12883-014-0247-3. PubMed PMID: 25516429.
   PubMed Web of Science ®Google Scholar
• Komai T, Shoda H, Yamaguchi K, et al. Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report. Mod Rheumatol 2016; 26(2):294–6. doi:10.3109/14397595.2013.861333. PubMed PMID: 24313919.
   Google Scholar
• Loschi M, Porcher R, Barraco F, et al. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. Am J Hematol 2016;91(4):366–70. doi:10.1002/ajh.24278. PubMed PMID: 26689746.
   PubMed Web of Science ®Google Scholar
• Nakayama H, Usuki K, Echizen H, et al. Eculizumab dosing intervals longer than 17 days may be associated with greater risk of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Biol Pharm Bull 2016;39(2):285–8. doi:10.1248/bpb.b15-00703. PubMed PMID: 26830487.
   PubMed Web of Science ®Google Scholar
• Mallett A, Hughes P, Szer J, et al. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. Intern Med J 2015;45(10):1054–65. doi:10.1111/imj.12864. PubMed PMID: 26247170.
   PubMed Web of Science ®Google Scholar
• Goncalves MV, Melo LH, Benedet CM, et al. Eculizumab, neuromyelitis optica, and tuberculosis: we live an era of challenging combinations. CNS Neurosci Ther 2015;21(11):914–5. doi:10.1111/cns.12465. PubMed PMID: 26404521.
   PubMed Web of Science ®Google Scholar
• Azzopardi L, Cox AL, McCarthy CL, et al. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol 2016;263(1):25–9. doi:10.1007/s00415-015-7925-y. PubMed PMID: 26477020.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Cotter J, Klingman J, et al. Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurol Neuroimmunol Neuroinflamm 2014;1(3):e34. doi:10.1212/NXI.0000000000000034. PubMed PMID: 25340086.
   PubMedGoogle Scholar
• Uygunoğlu, Pasha M, Saip S, et al. Recurrent longitudinal extensive transverse myelitis in a neuro-Behçet syndrome treated with infliximab. J Spinal Cord Med 2015;38(1):111–4. doi:10.1179/2045772314Y.0000000209. PubMed PMID: 24673549.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Miyake S. B-cell-directed therapy: which B cells should be targeted and how. Immunotherapy 2012;4(5):455–7. doi:10.2217/imt.12.35. PubMed PMID: 22642324.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, de Guibert S, et al. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br J Haematol 2016. doi:10.1111/bjh.13992. PubMed PMID: 27010483.
   Web of Science ®Google Scholar
• Kantarjian HM, Lioure B, Kim SK, et al. A phase II study of Coltuximab Ravtansine (SAR3419) monotherapy in patients with relapsed or refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2016;16(3):139–45. doi:10.1016/j.clml.2015.12.004. PubMed PMID: 26775883.
   PubMed Web of Science ®Google Scholar
• Hua F, Comer GM, Stockert L, et al. Anti-IL21 receptor monoclonal antibody (ATR-107): safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 2014;54(1):14–22. doi:10.1002/jcph.158. PubMed PMID: 23913720.
   PubMed Web of Science ®Google Scholar
• Vaknin-Dembinsky A, Brill L, Kassis I, et al. T-cell responses to distinct AQP4 peptides in patients with neuromyelitis optica (NMO). Mult Scler Relat Disord 2016;6:28–36. doi:10.1016/j.msard.2015.12.004. PubMed PMID: 27063619.
   PubMed Web of Science ®Google Scholar
• Saadoun S, Waters P, Leite MI, et al. Neuromyelitis optica IgG causes placental inflammation and fetal death. J Immunol 2013;191(6):2999–3005. doi:10.4049/jimmunol.1301483. PubMed PMID: 23935196.
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Ratelade J, Zhang H, et al. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 2013;73(1):77–85. doi:10.1002/ana.23741. PubMed PMID: 23055279.
   PubMed Web of Science ®Google Scholar